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Abstract
Background: Screening for colorectal cancer (CRC) has shown to reduce cancer-related mortality, however, acceptance and
compliance to current programmes are poor. Developing new, more acceptable non-invasive tests for the detection of
cancerous and precancerous colorectal lesions would not only allow preselection of individuals for colonoscopy, but may
also prevent cancer by removal of precancerous lesions.
Methods: Plasma from 128 individuals (cohort I – exploratory study: 73 cases / 55 controls ) was used to test the
performance of a single marker, SEPT9, using a real-time quantitative PCR assay. To validate performance of SEPT9, plasma
of 76 individuals (cohort II – validation study: 54 cases / 22 controls) was assessed. Additionally, improvement of predictive
capability considering SEPT9 and additionally ALX4 methylation was investigated within these patients.
Results: In both cohorts combined, methylation of SEPT9 was observed in 9% of controls (3/33), 29% of patients with
colorectal precancerous lesions (27/94) and 73% of colorectal cancer patients (24/33). The presence of both SEPT9 and ALX4
markers was analysed in cohort II and was observed in 5% of controls (1/22) and 37% of patients with polyps (18/49).
Interestingly, also 3/5 (60%) patients with colorectal cancer were tested positive by the two marker panel in plasma.
Conclusions: While these data confirm the detection rate of SEPT9 as a biomarker for colorectal cancer, they also show that
methylated DNA from advanced precancerous colorectal lesions can be detected using a panel of two DNA methylation
markers, ALX4 and SEPT9. If confirmed in larger studies these data indicate that screening for colorectal precancerous lesions
with a blood-based test may be as feasible as screening for invasive cancer.
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Introduction
Colorectal cancer (CRC) is the second most frequent cancer in
Europe and the US affecting 412,900 and 150,000 individuals in
2006, respectively [1,2]. CRC is also one of the leading causes of
cancer deaths in western countries, accounting for 207,400 deaths
in Europe in 2006 alone [2]. Interestingly, the number of deaths
from CRC has increased in Europe by 1.8% since 2004, despite
recent improvements in its diagnosis and therapy. While screening
has been shown to be effective in terms of reduction of disease-
related mortality and costs [3,4], the identification of early stages of
CRC or even precancerous lesions is hampered by the low
performance of non-invasive screening tests and the low acceptance
and compliance of invasive screening using colonoscopy.
A novel approach of molecular testing for CRC is the analysis of
DNA in stool. In a study published by Imperiale et al. [5], fecal
DNA testing was superior to FOBT in the detection of invasive
cancers and adenomas with high-grade dysplasia. Fecal DNA
testing was positive in 18% of individuals confirmed to have
advanced neoplasia (CRC or large adenomatous polyps) while
FOBT was positive in only 10.8%. Overall, fecal DNA studies
report sensitivities from 62 to 91% for CRC compared to 15–80%
for FOBT [6,7].
Evidence is increasing that, apart from genetic alterations,
epigenetic changes are of similar importance in the pathogenesis
of CRC. Particularly tumor suppressor genes can be silenced by the
methylation of CpG islands, which are found in the 59 region of
approximately half of all human genes [8,9]. Several groups have
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CRC, and transcriptional silencing in the tumor cells has been
reported for an increasing number of genes, including p16INK4,
MGMT, GSTP1, CDH1, APC and TIMP3 among many others
[10,11]. Besides, these epigenetic alterations occur already in the
early stages of tumor development, including precancerous lesions,
such as adenomas, which indicates that the analysis of epigenetic
DNA alterations may be useful for the diagnosis of malignant
diseases. Previously we independently detected a significant higher
prevalence of methylated ALX4 and SEPT9 DNA in peripheral
blood of colorectal cancer patients compared to controls [12,13].
Using SEPT9 methylated DNA, CRCs were predicted with a
sensitivity of 72% and a specificity of 93% [13]. Moreover, in one
study, large polyps were detected in approximately 20% of patients
using the analysis of SEPT9 methylation in peripheral blood [14].
Based on these previous reports on the potential use of SEPT9 for
the detection of early precancerous lesions we decided to further
evaluate this marker in patients with polyps. Therefore, we designed
this study, including an exploratory and a validation study, in order
to further assess the performance of SEPT9 methylated DNA as a
marker in the detection of colorectal precancerous lesions. In the
validation study, we included also methylated ALX4 DNA to test if
the predictive value for polyps increases if an additional marker is
used, this has to be further validated, however. Since early non-
invasive detection of polyps could be followed by endoscopic
removal of precancerous lesions, this strategy might help to prevent
more invasive colorectal cancers.
Methods
Subjects for Methylation Analysis
The entire study population was assembled by two seperate
cohorts. For cohort I (exploratory cohort), plasma was collected
from 128 individuals with different clinical characteristics: healthy
controls (n=12), patients with symptomatic non-malignant bowel
diseases with or without positive FOBT (n=17), patients with a
history of polypectomy or family history for colorectal neoplasia
(n=6), patients with chronic inflammatory diseases of the
gastrointestinal tract (n=20), 45 patients with colorectal precan-
cerous lesions and 28 patients with CRC (Table 1).
For cohort II (validation cohort), plasma samples were collected
from 76 individuals prior to any intervention: 49 patients (18
female, 31 male) with colorectal precancerous lesions (36 with
adenomas, 13 with hyperplastic polyps; patients’ median age 63
years, range 20–75 years), from 22 healthy controls (11 female, 11
male; median age 42.5 years, range 25–69 years) without
colorectal lesions and 5 patients (2 female, 3 male) with CRCs
(median age 59 years, range 27–79 years; 4 patients UICC stage I,
1 patient UICC stage III, Table 1).
Biopsies were taken during resection and/or endoscopy and
were formalin fixed [15]. Sections were stained with hematoxylin
and eosin for histological evaluation [15]. Five randomly selected
CRC patients were included in this analysis and served as positive
controls. In all cases tumor stages were assessed using the TNM-
system according to the guidelines of the Union Internationale
Contre Le Cancer (UICC) [16]. This study was approved by the
Ethics Committee of the Technical University Munich, Germany.
Written consent from all patients was obtained.
DNA Extraction
Genomic DNA was either extracted from 12 ml plasma using a
MagnaPureH device (Roche) and the MagNAPure LC Total
Nucleic Acids Large Volume Extraction Kit (Roche Diagnostics
#03264793001) as previously reported [12] or was extracted and
bisulfite converted using the SEPT9 Detection Assay (Epigenomics
#M4-01-003). SEPT9 methylation analysis was done by Heavy
MethyLight as described below. The assay workflow yielded 2–
5 mg/l circulating plasma DNA following bisulfite treatment.
Recovery was, thus, 45–50% of genomic DNA, similar to previous
reports (Figures S1 and S2) [13].
SEPT9 Methylation Analysis by Heavy MethyLight
SEPT9 methylation was determined using the HeavyMethyl
technique [17]. In the HeavyMethyl technique four oligonucleo-
tides are used per reaction including two non-methylation specific
PCR primers, one with an overlapping blocker sequence specific
for unmethylated DNA, flanking a methylation specific probe. The
forward primer for SEPT9 was 59-GTAGTAGTTAGTTTAG-
TATTTATTTT-39, the reverse primer was 59-CCCACCAACC-
ATCATAT-39. Probe sequences were GTTCGAAATGATTT-
TATTTAGTTGC-FL and LC-Red640-CGTTGATCGCGG G-
GTTC-PH. The blocker sequence was 59-CATCATATCA-
AACCCCACAA TCAACACACAAC-39. A C3 spacer was
introduced at the 39 end of this sequence.
ALX4 Methylation Analysis by Quantitative Real-Time
PCR
Genomic DNA was analysed by the MethyLight technique after
bisulfite conversion as previously reported [18,19]. In the Methy-
Light analysis three oligonucleotides are used in every reaction.
Two locus-specific PCR primers flank an oligonucleotide probe
with a 59 fluorescent reporter dye (6FAM) and a 39 quencher dye
(BHQ-1). For this analysis primers and probes are specifically
designed to bind to bisulfite-converted DNA, which generally span
7 to 10 CpG dinucleotides. The gene of interest is then amplified
in case of complete methylation. The specificity of the reactions for
methylated DNA is confirmed using human sperm DNA
(unmethylated) and CpGenome Universal Methylated DNA
(Chemicon (subsidiary of Serologicals) catalog #S7821) (methyl-
ated). The primer and probe sequences were sALX4f, 59-
CGTCGCAACGCGTACG-39, sALX4r, 59-CGCGGTTTCGA-
TTTTAATGC-39. Probe sequences were 59-ACTCCGACT-
TAACCCGACGATCG-39 and 59-ACGAAATTCCTA ACG-
CAACCGCT-39 [12]. No sequencing was performed and no new
data added to Genbank.
Statistical Analysis
The results of the MethyLight and HeavyMethyl assays were
interpreted in a purely qualitative way as previously reported [14].
We confirmed that the sensitivity of the MethyLight and
HeavyMethyl assays are equivalent in previous studies [13,14].
The limit of detection (LOD) was 25 pg for these assays which
were performed as previously reported [14] (Supplementary file 2).
For the qualitative analysis of two methylation markers, amplifi-
cation curves above the baseline indicated presence of methylated
DNA in the plasma samples. The different clinicopathological
features, such as size of lesion and histologic subtype of lesion were
used as categorial variables. Frequency distribution of these
parameter values were compared using the Fisher’s exact test or
Chi square test. All tests were two-sided, and a p-value of ,0.05
was considered statistically significant [18,19]. To retain a
maximum of power in the primary interesting analyses, no
correction of alpha error rate in consideration of the multiple test
issue was performed. Concerning this matter, we follow a more
practical solution: as suggested by Saville [20], corrections for
multiple comparisons are not performed but all available data and
comparisons made are honestly reported allowing the reader to
Adenoma Detection in Plasma
PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9061draw the conclusions. So the reader can informally adjust for
multiple comparisons while reviewing the data.
Results
Single Marker Analysis in Plasma Samples (Cohort I -
Exploratory Cohort)
First, we determined the presence of a single DNA methylation
marker in plasma from patients with colorectal precancerous lesions,
CRC, in healthy controls without any colorectal pathology, patients
with chronic inflammation, or other gastrointestinal diseases and
patients with a high risk for CRC due to family history or positive
FOBT (Table 2). All methylation marker measurements were
performed in triplicate. For the analysis of the marker panel
performance two different classification methods were selected. The
first method classified patients as positive if both single marker
classifications were positive (2 or 3 measurements). The second
method classified patients as positive if independent of the marker any
three of the total six PCR reactions showed amplification.
SEPT9 m e t h y l a t e dD N Ai n1o f3m e a s u r e m e n t sw a sd e t e c t e di n3
out of 12 healthy controls (25%), 28 out of 45 patients with polyps
(62%), 25 out of 28 (89%) patients with colorectal cancers, 18 out of
20 (90%) patients with chronic inflammation and 6 of 6 high risk
patients as well as 17 out of 17 patients with symptomatic diseases.
Using the cut-off of at least 2 or 3 positive measurements only 2 of 12
healthy controls(17%),9 of 17 symptomatic patients (53%),4 of 6 risk
patients (67%), 10 of 20 patients with inflammation (50%), 21 of 45
patients with colorectal precancerous lesions (47%) and 22 of 28
CRC patients (79%) were classified as positive (Table 2).
Single Marker Analysis in Plasma Samples (Cohort II -
Validation Cohort)
Since in the exploratory study positive SEPT9 levels were found
in various non-malignant intestinal diseases, we used a second
Table 1. List of patients and clinical data for cohort I (exploratory) and cohort II (validation).
Cohort I (exploratory)
Total Samples Male/Female Median Age Age Range Disease
Normal 12 5 / 7 60.5 52–72 healthy, no symptoms
Polyp 45 2 / 8
35 not stated
64
(10 patients)
44–71 35 unclassified adenomas
5 tubular adenomas
1 serrated adenoma
3 high grade invasive tubular adenomas
1 high grade invasive tubulo-villous
CRC 28 2 / 2
24 not stated
67
(4 patients)
63–71 5 stage 0
2 stage I
14 stage IV
7 unknown stage
Inflammation 20 2 / 7
11 not stated
61
(9 patients)
31–80 9 colitis or gastritis
1 anastomositis
1 ulcus
1 collagene colitis
1 M. Crohn
1 NSAID-colopathy with positive FOBT
1 antibiotics
1 diverticulitis
2 recurring diarrhea
1 diarrhea and positive FOBT
1 diarrhea and bowel pain
Risk patient 6 3 / 3 47.5 39–68 2 after polpectomy
2 familial history
2 M2-PK positive
Symptomatic 17 9 / 8 57 22–84 6 positive FOBT
3 irregular stool
2 constipation
2 bleedings
1 loosing weight
1 flatulence
2 bowel pains
128
Cohort II (validation)
Total Samples Male/Female Median Age Age Range Disease
Normal 22 11 / 11 42.5 25–69
Polyp 49 31 / 18 63 20–75 36 adenomas, 13 hyperplastic polyps
CRC 5 3 / 2 59 27–79 4 stage I
1 stage III
Total 76
doi:10.1371/journal.pone.0009061.t001
Adenoma Detection in Plasma
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9061cohort to assess the performance of SEPT9 in comparison to
asymptomatic healthy controls. SEPT9 methylated DNA in 1 of 3
measurements was detected in 1 of 22 (5%) healthy controls. In
contrast, SEPT9 methylation was significantly more frequent in
patients with polyps (15 of 49 patients (31%); p=0.01). Using the
cut-off of at least 2 or 3 positive measurements with regard to the
presence of SEPT9 methylated DNA in plasma, again only 1 of 22
(5%) healthy controls was classified as positive, whereas patients
with polyps exhibited methylated SEPT9 DNA in at least 2
measurements in 6 of 49 (12%) cases. Cancer patients were
positive in 2 of 5 cases using either classification (Table 2).
Single Marker Analysis in Exploratory + Validation Cohort
Combining the data from both cohorts for methylated SEPT9
DNA gave the following results: Under the high specificity criteria,
3 out of 34 (9%) healthy controls and 27 out of 94 polyp patients
(29%) as well as 24 out of 33 (73%) CRC patients were classified as
positive. The difference in prevalence of SEPT9 DNA between
polyp and control samples was statistically significant (p=0.02,
Table 2). Using the high sensitivity determination, the positive
fraction in the healthy controls raised to 4 out of 34 (12%),
whereas 43 out of 94 polyp (46%) and 27 out of 33 (82%) cancer
patients were considered positive. Again the difference between
polyps and normal controls was statistically significant (p=0.0004,
Table 2).
Analysis of Marker Panel Performance in Plasma Samples
In order to improve the detection rate of SEPT9 in patients with
colorectal precancerous lesions, we performed a two marker panel
analysis in the validation cohort. First we assessed the performance
of the single marker ALX4 in these patients. In the high sensitivity
determination, ALX4 methylation was detectable in 13 of the 22
healthy controls (59%), 38 of the 49 polyp patients (78%) and in 4
of 5 (80%) cancer patients. Using the more stringent criteria (high
specificity) the number of healthy controls with positive DNA
detection decreased to 4 of 22 individuals (18%), whereas for
patients with polyps 22 of 49 patients (45%) were considered
positive (p=0.02). Methylated DNA was observed in 2 of 5 cancer
patients (Table 3).
Next, we analysed the two marker panel with regard to
performance in the detection of colorectal precancerous lesions.
Again, two different levels of stringency with regard to the
presence of methylated DNA in plasma samples were applied.
Using SEPT9 + ALX4 and classifying a sample as ‘‘positive’’ if any
of the single markers is ‘‘positive’’ (at least 2 of the 3
measurements), we observed 4 positive cases among the 22
healthy controls (18%), 25 positive cases among the 49 patients
with polyps (51%) and 3 positive cases among the 5 cancer patients
(Table 4). Thus, there was a significantly higher frequency of
methylated markers in plasma of patients with polyps versus
healthy controls (p=0.0068).
Applying the less stringent criteria of at least 3 positive
measurements among the 6 combined measurements of both
markers, 1 of 22 healthy controls was classified as positive (5%),
w h e r e a s1 8o f4 9p a t i e n t sw i t hp o l y p s( 3 7 % )a n d ,a g a i n ,3o f5c a n c e r
patients were found to be positive. The difference between normals
and polyps was highly statistically significant (p=0.0013) (Table 4).
Marker Performance and Subclassification of Polyps
Next we turned to the analysis of marker performance with
respect to the different types of polyps analysed in our study. Polyps
were subclassified with respect to the clinically relevant size of
,10 mm and $10 mm and histomorphological criteria (e.g.
tubular or tubulovillous type, presence of high grade or low grade
intraepithelial neoplasia). Patients with tubular or tubulo-villous
adenomas irrespective of size were positive with regard to the
presence of the marker panel in blood in 19 of 36 (53%) patients.
The frequency of detectable methylated DNA increased in the
subclass of patients with adenomas $10 mm (69%, 11 of 16). In the
subgroup of polyps $10 mm and the presence of high grade
intraepithelial neoplasia methylated DNA of the two markers was
even observed in the plasma in 5 of 7 cases (71%; Table 5). Overall,
methylation markers were significantly more frequent in patients
with advanced colorectal adenomas compared to healthy controls
(p,0.001). Using a panel of the 2 markers in plasma, sensitivity and
Table 2. Analysis of SEPT9 methylation in plasma samples.
cohort I (exploratory) 2/3 positive 1/3 positive
SEPT 9
Total
Samples
Patients
(n) %
Patients
(n) %
Normal-healthy
control
12 2 17 3 25
Polyp 45 21 47 28 62
CRC 28 22 79 25 89
Inflammation 20 10 50 18 90
High risk patient 6 4 66 6 100
Symptomatic
patient
17 9 53 17 100
cohort II (validation) 2/3 positive 1/3 positive
Normal-healthy
control
22 1 4.5 1 4.5
Polyp 49 6
$ 12 15* 31
CRC 5 2 40 2 40
both cohorts combined 2/3 positive 1/3 positive
Normal-healthy
control
3 4 394 1 2
Polyp 94 27
& 29 43
1 46
CRC 33 24 73 27 82
p-values Fisher’s exact test (2-sided) polyp vs. normal:
$0.43;
*0.01;
&0.02 ;
10.0004.
doi:10.1371/journal.pone.0009061.t002
Table 3. Analysis of ALX4 methylation in plasma samples
cohort II (validation).
2/3 positive 1/3 positive
ALX4
Total
Samples
Patients
(n) %
Patients
(n) %
Normal-healthy
control
22 4 18 13 59
Polyp 49 22* 45 38
$ 77.5
CRC 5 2 40 4 80
p-values Fisher’s exact test (2-sided) polyp vs. normal:
$0.15;
*0.02
doi:10.1371/journal.pone.0009061.t003
Adenoma Detection in Plasma
PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e9061specificity for the detection of advanced precancerous colorectal
lesions was 71% and 95%, respectively (Tables S1 and S2).
Discussion
The main problem of CRC screening today is low compliance
in existing screening programmes. Despite the fact that CRC has
all features which qualify this disease for mass screening, including
high incidence and prevalence, high mortality in advanced disease,
potential for cure in early stages, on average less than 30% of the
eligible population in the US and Europe actually undergo these
preventive procedures [3,4]. Preselection of individuals with
precancerous or early neoplastic lesions with a patient-friendly
non-invasive molecular test followed by colonoscopy for diagnosis
and potential removal of these lesions, may not only improve
compliance and acceptance of invasive screening, but may also
have the potential to prevent cancer.
Based on the presence of certain genetic, epigenetic and related
changes in the proteome of CRCs it has been tempting to assess
the diagnostic accuracy of the presence of these changes in blood
and stool for the purpose of CRC screening [5–7,10,11]. Until
recently molecular colorectal testing has been based on the
detection of genetic changes in stool. However, fecal DNA testing
is expensive and the limited performance of these tests do not
allow wide spread use as a molecular CRC screening tool
[3].
Another non-invasive approach is the detection of epigenetic
changes in blood and/or stool of patients with CRC (Tables S3
and S4). Several groups have reported a high frequency of
methylated genes in CRC and in the stool of patients with CRC.
Recently, we reported the identification of SEPT9 and ALX4 gene
methylation as potential markers for CRCs [12–14]. Using a cut-
off of 41.4 pg/ml, sensitivity and specificity of ALX4 methylation
in plasma was 83.3% and 70%, respectively [12]. In addition,
recent analysis of SEPT9 methylation in plasma revealed a
sensitivity of 70% and specificity of 90% for the detection of
patients with CRC [13,14]. Based on these promising data we
aimed to assess the potential role of these markers, both as single
markers and as a panel, for the detection of colorectal
precancerous lesions, i.e. for colorectal adenomas.
Similar to our previous reports on ALX4 and SEPT9
methylation in CRC patients [12–14], we found a high frequency
of DNA methylation in plasma of patients with colorectal
adenomas. Thus, we observed a significantly higher frequency of
ALX4 and SEPT9 methylated DNA in plasma from patients with
polyps versus healthy controls. In addition, the combined analysis
of the two markers proved to be highly significant in the detection
of colorectal polyps with a sensitivity and specificity reaching 71%
and 95%, respectively, for the detection of advanced precancerous
colorectal lesions. Thus, the performance of this marker panel was
further enhanced after the detailed analysis of the histomorpho-
logical nature of the lesions that were observed in the patients with
polyps. Accordingly, the combination of the two markers proved
to be highly sensitive in the detection of advanced adenomas,
which are defined clinically and pathologically as lesions that are
$10 mm in size and exhibit features of potential malignant
transformation (high grade intraepithelial neoplasia, villus com-
ponent of adenoma, etc.).
Recently, other groups have also analysed the presence of
methylation markers in body fluids from patients with CRCs and
adenomas, with a special emphasis on molecular stool analysis.
However, the sensitivity of single methylation markers does not
exceed 57% and in blood almost none of these markers were
found so far (Tables S3 and S4). Using qualitative methylation
analysis based on realtime conditions we could detect methylated
DNA in up to 71% of individuals with advanced adenomas. Our
Table 5. Analysis of marker performance with regard to polyp histology.
Polyp characteristics Cases SEPT9 2/3
x ALX4 2/3 SEPT9 or ALX4 2/3 SEPT9 + ALX4 3/6
Patientts
(n) %
Patientts
(n) %
Patientts
(n) %
Patientts
(n) %
. or = 10 mm 18 3 17 9
o 50 12
x,1 67 9
1 50
,10 mm 31 3 10 13
o 42 13* 42 9
o 29
Hyperplastic 13 1 8 6
x 46 6
x 46 4
x 31
Tubular or tubulovillous adenoma-all sizes 36 5 14 16
o 44 19
o 53 14
1 39
Tubular or tubulovillous adenoma, .10 mm 16 3 19 8
o 50 11
1 69 8
1 50
Tubular or tubulovillous, .10 mm + aIEN 7 1 14 4
x 57 5
o 71 5* 71
Normal control 22 1 4.5 4 18 4 18 1 5
Legend: x, polyp versus normal: not significant;
o, lesion versus normal colon: p,0.05;
$, polyp size $10 mm versus ,10 mm: p,0.05;
1, lesion versus normal colon: p,0.005;
*, lesion versus normal colon: p,0.001; aIEN, advanced intraepithelial neoplasia.
doi:10.1371/journal.pone.0009061.t005
Table 4. Two marker panel analysis in plasma – high
specificity criteria and high sensitivity criteria.
2/3 positive either
assay 3/6 positive
SEPT 9 and
ALX4
Total
Samples
Patients
(n) %
Patients
(n) %
Normal-healthy
control
22 4 18 1 5
Polyp 49 25
$ 51 18
* 37
CRC 5 3 60 3 60
p-values Fisher’s exact test (2-sided) polyp vs. normal:
$0.0068;
*0.0013.
doi:10.1371/journal.pone.0009061.t004
Adenoma Detection in Plasma
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9061panel of markers is the first demonstration in blood of advanced
precancerous colorectal lesion detection to show better perfor-
mance than other marker panels tested in stool only (Tables S3
and S4).
We also analysed the methylation status by including other
symptomatic patients groups with non-malignant intestinal
diseases. Methylation of SEPT9 was increased among high risk
patients (67%) and patients with chronic inflammation (50%).
Thus, our exploratory study indicates that SEPT9 may be able to
identify potentially curable early cancers or even precancerous
colorectal lesions in asymptomatic individuals. However, patients
with concomitant inflammatory diseases or other increased cancer
risk should be directed to colonoscopy according to current clinical
routine without non-invasive first line screening [21,22].
In conclusion, our study presents the first evidence for a novel
approach for the detection of advanced precancerous colorectal
lesions using methylation markers in plasma. Advanced precan-
cerous colorectal lesions are associated with an increased
frequency of methylated DNA in the plasma. Based on this study,
the diagnosis of colorectal precancerous lesions may be possible
with a non-invasive, sensitive and reliable plasma-based test using
a panel of methylation markers. If confirmed in a larger patient
population, a diagnostic test based on this panel could improve
early detection of cancerous lesions by allowing preselection of
patients with precancerous colorectal lesions that could be
subsequently be removed by colonoscopy, thereby offering the
potential to prevent colorectal cancer.
Supporting Information
Figure S1 Performance comparison of HM/Methylight assays
on tissue samples. 198 Colorectal cancer tissues and 22 normal
colon mucosa samples were analyzed by quantitative real-time
PCR. Performance for the HM/Methylight is demonstrated by
ROC plot analysis.
Found at: doi:10.1371/journal.pone.0009061.s001 (3.88 MB TIF)
Figure S2 Performance comparison of MSP/Methylight assays
on tissue samples. 198 Colorectal cancer tissues and 22 normal
colon mucosa samples were analyzed by quantitative real-time
PCR. Performance for the MSP/Methylight is demonstrated by
ROC plot analysis.
Found at: doi:10.1371/journal.pone.0009061.s002 (3.83 MB TIF)
Table S1 Classification table: Marker panel for detection of
advanced polyps.
Found at: doi:10.1371/journal.pone.0009061.s003 (0.03 MB
DOC)
Table S2 Summary of statistical results.
Found at: doi:10.1371/journal.pone.0009061.s004 (0.04 MB
DOC)
Table S3 Performance of methylation markers in stool and
blood for detection of colorectal adenoma.
Found at: doi:10.1371/journal.pone.0009061.s005 (0.04 MB
DOC)
Table S4 Results of multipanel assays with methylation markers
for diagnosis of colorectal cancer in stool.
Found at: doi:10.1371/journal.pone.0009061.s006 (0.03 MB
DOC)
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